Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133477) titled 'Low-Dose Radiotherapy Combined with Retilrafusp alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma' on Sept. 28.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: harbin medical university cancer hospital
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Intervention:
Cohort 1: Low-dose Radiotherapy + Retilrafusp alfa + Chemotherapy:1. Low-dose radiotherapy: 8 Gy/4 fractions, 2 Gy per fraction, delivered to the primary lesion and metastatic lymph nodes.
2. Relafuspa (d1, 1800 mg or 30 mg/kg, q3w, for a total...